There are 1105 resources available
715P - Impact of serum anti-p53 antibody on efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Tetsuo Shimizu
Session: Poster Display session
Resources:
Abstract
716P - A new model for identification of lung cancer metastasis cells in cerebrospinal fluid
Presenter: Jingwen Feng
Session: Poster Display session
Resources:
Abstract
717P - Non-SqCC EGFR-mutant NSCLC patients with RAS-PI3K-AKT-RAF alterations have poorer response to EGFR-TKIs and overall survival
Presenter: Yi-Chun Hsiao
Session: Poster Display session
Resources:
Abstract
718P - EML4-ALK gene variants and PD-L1 expression: Their Impact on clinical outcomes in ALK-positive NSCLC
Presenter: Santhosh Meedimale
Session: Poster Display session
Resources:
Abstract
719P - Genomic profiling of driver gene alterations in patients with non-small cell lung cancer, patterns of treatment and impact on survival outcomes: A single center experience of more than 1200 patients
Presenter: Minit Shah
Session: Poster Display session
Resources:
Abstract
720P - Interleukin gene expression and their impact on prognosis in metastatic NSCLC
Presenter: Santhosh Meedimale
Session: Poster Display session
Resources:
Abstract
721TiP - A phase I/II study of davutamig (REGN5093), a MET×MET bispecific antibody, in patients with MET-altered, advanced non-small cell lung cancer (aNSCLC): Trial in progress update
Presenter: Myung-Ju Ahn
Session: Poster Display session
Resources:
Abstract
722TiP - Efficacy and safety of combination therapy of sintilimab and chemotherapy with cryoablation in the first-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Bo Zhang
Session: Poster Display session
Resources:
Abstract
723TiP - Liposomal irinotecan (Lipo-IRI) alone or in combination with famitinib or platinum for patients with extensive-stage small cell lung cancer (ES-SCLC) after failure of first-line immunotherapy: A multicenter, randomized, open-label, multicohort phase II trial
Presenter: Haiyan Xu
Session: Poster Display session
Resources:
Abstract
724TiP - Phase II study of aumolertinib combined with metronomic oral vinorelbine and a platinum-based agent in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer
Presenter: Xinli Hou
Session: Poster Display session
Resources:
Abstract